A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD-P to VAD-P/Quinine for Induction; (2) Randomization of Prednisone Dose Intensity For Remission Maintenance

Association of Patient Demographic Characteristics and Insurance Status with Survival in Cancer Randomized Clinical Trials with Positive Findings

JM Unger;CD Blanke;M Leblanc;W Barlow;R Vaidya;M Fleury;SD Ramsey;DL Hershman JAMA Network Open Apr 1;3(4):e203842

PMid: PMID32352530 | PMC number: PMC7193331

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials

BGM Durie;J Jacobson;B Barlogie;J Crowley Journal of Clinical Oncology 22(10):1857-1863

A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience

JL Jacobson;MA Hussein;B Barlogie;BGM Durie;JJ Crowley British Journal of Haematology 122:441-450

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

JR Berenson;JJ Crowley;TM Grogan;J Zangmeister;AD Briggs;GM Mills;B Barlogie;SE Salmon Blood 99(9):3163-3168

Standard-dose therapy for multiple myeloma: the Southwest Oncology Group experience

J Crowley;J Jacobson;R Alexanian Seminars in Hematology 38(3):203-208

Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma patients.

J Berenson;J Crowley;B Barlogie;S Salmon Blood 92(10(Suppl.1):318a(#1305)